Loading patent…
AssigneeCybin IRL Limited
InventorsAlex Nivorozhkin, Michael Palfreyman, Pradip M. Pathare, Kenneth L. Avery, Mohammed I. Shukoor, Michael E. Morgan, Joan M. Krakowsky, Amir Inamdar, Pradeep J. Nathan, Sebastian Krempien
Estimating the term…
The present disclosure relates generally to methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
A method of treating a depressive disorder in a subject in need thereof, comprising administering orally to the subject about 8 mg to about 16 mg (free base equivalence) of a compound of Formula (I-3)
A pharmaceutical composition, comprising:
An adjunctive therapy method for treating a depressive disorder in a subject taking an antidepressant medication as part of ongoing treatment, the adjunctive therapy method comprising administering to the subject about 8 mg to about 16 mg (free base equivalence) of a compound of Formula (I-3)
A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering orally to the subject a capsule comprising about 8 mg to about 16 mg (free base equivalence) of a benzenesulfonate salt of a compound of Formula (I-3)
A method of treating major depressive disorder (MDD) in a subject in need thereof, comprising administering orally to the subject an oral liquid dosage form comprising:
Dependencies are inferred from the claim text.